Novartis Vaccines & Diagnostics GmbH, Emil-von-Behring-Strasse 76, D-35041 Marburg, Germany.
Future Microbiol. 2011 Feb;6(2):143-52. doi: 10.2217/fmb.10.161.
After more than 60 years, the conventional production of influenza vaccines employing fertilized chicken eggs has reached its limits - both in terms of temporal flexibility and vaccine production volume. This problem is compounded by the fact that the pandemic-driven situation in 2009 has roughly doubled the overall vaccine demand. Modern cell culture technology has significant advantages over the conventional method of manufacturing influenza vaccines employing embryonated chicken eggs, and enables manufacturers to respond rapidly to the increasing worldwide seasonal and pandemic-driven need for influenza vaccines. Recent articles in the popular press claiming that cell culture-based influenza vaccines can cause tumors have fomented uncertainty among the general population and physicians, and also discredit officially accepted test results and product licensing. This article provides an overview of the safety profile of the cell culture technology, of the cells and of the final vaccine product.
经过 60 多年，传统的鸡胚生产流感疫苗的方法在时间灵活性和疫苗生产数量方面都已经达到了极限。2009 年大流行导致的情况使总体疫苗需求增加了近一倍，这使得这个问题更加复杂。现代细胞培养技术与传统的鸡胚生产流感疫苗的方法相比具有显著优势，使制造商能够迅速应对全球季节性和大流行流感疫苗需求的增加。最近流行媒体上的一些文章声称，基于细胞培养的流感疫苗会导致肿瘤，这引起了普通民众和医生的不确定性，也使官方认可的测试结果和产品许可受到质疑。本文概述了细胞培养技术、细胞和最终疫苗产品的安全性概况。
